Assetmark Inc. Grows Holdings in IQVIA Holdings Inc. $IQV

Assetmark Inc. raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 6.3% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 183,483 shares of the medical research company’s stock after purchasing an additional 10,858 shares during the period. Assetmark Inc.’s holdings in IQVIA were worth $31,291,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in IQVIA by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after acquiring an additional 159,899 shares during the period. Geode Capital Management LLC boosted its holdings in shares of IQVIA by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after buying an additional 24,453 shares during the last quarter. Boston Partners grew its position in IQVIA by 14.9% during the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock valued at $923,276,000 after buying an additional 530,672 shares during the period. JPMorgan Chase & Co. increased its holdings in IQVIA by 16.2% during the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after buying an additional 528,753 shares during the last quarter. Finally, Invesco Ltd. raised its position in IQVIA by 15.3% in the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after acquiring an additional 367,204 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IQV. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research note on Thursday, July 9th. Robert W. Baird upped their price objective on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research note on Wednesday, July 1st. Mizuho raised their target price on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Evercore restated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Finally, HSBC reiterated a “buy” rating and set a $240.00 price target on shares of IQVIA in a research note on Monday, July 6th. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $225.71.

IQVIA Trading Down 2.0%

NYSE:IQV opened at $206.26 on Friday. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $247.04. The stock’s fifty day moving average price is $185.04 and its two-hundred day moving average price is $188.16. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The company has a market cap of $34.42 billion, a P/E ratio of 25.56, a P/E/G ratio of 1.85 and a beta of 1.20.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its board has approved a share repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.